Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Merck (NYSE:MRK) experienced a 4% price move over the last month, driven by crucial developments in its product offerings. The FDA approval of ENFLONSIA for RSV prevention and the successful clinical ...

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...